| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal HST23: Asfotase alfa for treating paediatric-onset hypophosphatasia (review of HST6) |
|
Medicine details |
|
| Medicine name | asfotase alfa (Strensiq®) |
| Formulation | 40 mg/ml and 100 mg/ml solution for injection |
| Reference number | 2234 |
| Indication | For long-term enzyme replacement therapy in patients with paediatric-onset hypophosphatasia to treat the bone manifestations of the disease |
| Company | Alexion Pharma UK Ltd |
| BNF chapter | Nutrition & blood |
| Assessment type | Non-submission |
| Status | Excluded due to NICE appraisal |
| Date of issue | 16/11/2017 |
| NICE guidance | HST23: Asfotase alfa for treating paediatric-onset hypophosphatasia (review of HST6) |